PRT logo

PermRock Royalty Trust Trust Unit

PRT—
Earnings Dec 2US Equity
$1.43▲ $0.00 (+0.35%)
🌙 After hours$1.42▼ 0.70%Regular close · extended-hours price shown
🔔
Track PRT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.3%
7d▼ 0.7%
14d▼ 19.4%
30d▼ 26.9%
ytd▼ 49.0%
1y▼ 64.3%
🏦Market Cap
—
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.38 – $1.45
52-Week Range
—
Volume (shares)
34,156
Avg Volume (shares)
—
Shares Outstanding
—
Next Earnings
2026-12-02

Fundamentals Snapshot

Annual Revenue
$6M
Last Q Revenue
$706,672
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+0.0%
PRT logo

PermRock Royalty Trust Trust Unit

PRT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6M▼ −6.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$5M▼ −8.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$0
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
12.2M▲ +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1.2B▲ +$1.2B YoY
StockOtter · stockotter.space

About PermRock Royalty Trust Trust Unit

A company profile for PermRock Royalty Trust Trust Unit isn’t available yet — check back soon.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Sell
8 analysts
Strong Buy0
Buy0
Hold3
Sell4
Strong Sell1
Ratings as of Nov 2022

Latest News & Updates

PRNewsWire·9d ago

PermRock Royalty Trust Declares Monthly Cash Distribution

DALLAS, Oct. 20, 2026 /PRNewswire/ -- PermRock Royalty Trust (NYSE: PRT) (the "Trust") today declared a monthly cash distribution to record holders of its trust units representing beneficial interests in the Trust ("Trus

GlobeNewsWire·16d ago

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

Combination cohorts are part of Prelude's Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment in the fourth quarter of 2026

Defense World·18d ago

PermRock Royalty Trust (NYSE:PRT) Shares Down 1.1% – Here’s Why

PermRock Royalty Trust (NYSE: PRT - Get Free Report)'s stock price traded down 1.1% during trading on Friday. The company traded as low as $1.75 and last traded at $1.77. 32,806 shares were traded during mid-day trading,

Defense World·Sep 28

PermRock Royalty Trust (PRT) To Go Ex-Dividend on September 30th

PermRock Royalty Trust (NYSE: PRT - Get Free Report) announced a monthly dividend on Friday, September 18th. Investors of record on Wednesday, September 30th will be given a dividend of $0.0196 per share on Thursday, Oct

GlobeNewsWire·Sep 10

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

WILMINGTON, Del., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cleared the Company to